12.02 Daily Digest
Leave a CommentI apologize for not writing since the week-end of Thanksgiving. The combination of relocating my family and the heavy work load that has been provided by my clients has left with me little time to update the blog this past week.
Rest assured that I will send you the monthly market insider newsletter (if you are on my list- contact me at cjeannot(at)mrica.com if not) end of this week with all updated news up to the beginning of December.
I appreciate the understanding as I work hard to find time to update the neuro blog.
11.30 Daily Digest
UNIVERSITY/MEDICAL CENTER STUDIES
Chronic Pudental Neuromodulation- Alternative to Sacral Neuromodulation for Urological Symptoms. Overall positive pudendal response was achieved in 71.4%. 93% of those who failed sacral neuromodulation were considered successful. Learn More (Peters KM, Killinger KA, Boguslawski BM, Boura JA)
11.29 Daily Digest
EARNINGS
Medtronic Reports 2Q10 revenue of $3.838 Billion, +8%. Neuromodulation revenue of US $384MM, +12%. Learn More
11.26-11.28 Daily Digests
No market news.
11.25 Daily Digest
UNIVERSITY/MEDICAL CENTER STUDIES
Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation. Department of Urology, University of Iowa notes outcomes of 39 patients 22 that went from test stimulation to permanent generator implantation from 01/00 to 07/04. There were significant differences in short-term but not long-term outcomes between the 2 methods of test stimulation. Learn More
11.24 Daily Digest
EARNINGS
Medtronic Reports 2Q10 revenue of $3.838 Billion, +8%. Neuromodulation revenue of $384MM, +12% from 2Q09, driven by strong sales of Activa® PC and RC Deep Brain Stimulation systems for movement disorders, and InterStim® Therapy used to treat urinary and bowel incontinence. Learn More
11.23 Daily Digest
FEATURED PROCEDURES
Sacral Neuromodulation Control Curess 55-Year Old Women’s Incontinence (UK). Sue Jacobs passes on repeat Botox injections to bladder sides and involves a 20% risk of paralysing the bladder muscles, (at which points patients require a catheter to pass urine.) and chooses sacral neuromodulation. Learn More
11.22 Daily Digest
No market news.
11.21 Daily Digest
FEATURED EXECUTIVES
MicroTransponder CEO Will Rosellini Named Graduate Student Entrepreneur of the Year by the Entrepreneurs’ Organization (EO). Rosellini was recognized for his vision and drive to create a dynamic neurostimulation company that is developing products to treat a range of neurological disorders including tinnitus, stroke, Parkinson’s disease, and chronic pain. Learn More
